NDAINTRAVENOUSSOLUTION
Approved
Apr 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
7/8 — Comprehensive
AKYNZEO (fosnetupitant and palonosetron) by Helsinn is serotonin 3 receptor antagonists [moa]. Approved for combination with dexamethasone in adults for the prevention of acute, delayed nausea, vomiting associated with initial and 5 more indications. First approved in 2018.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AKYNZEO is a fixed-dose combination IV antiemetic containing fosnetupitant (NK1 antagonist) and palonosetron (5-HT3 antagonist) approved for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). It is administered with dexamethasone in adults receiving highly emetogenic cancer chemotherapy. The dual mechanism targets multiple pathways in the emetic cascade for superior efficacy versus single-agent antiemetics.
$0.441MPart D
Peak11.1 years to LOEProduct is at peak commercial maturity with modest Part D spending (~$441K in 2023); brand team focus likely on maintaining market position and preparing for LOE-related strategic transitions.
Mechanism of Action
Serotonin 3 Receptor Antagonists
Pharmacologic Class:
Serotonin-3 Receptor Antagonist
Worked on AKYNZEO at Helsinn? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.